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Abstract
Obesity, and resultant health hazards which include diabetes, cardiovascular disease and metabolic syndrome, are
worldwide medical problems. Control of diet and exercise are cornerstones of the management of excess weight.
Foods with a low glycemic index may reduce the risk of diabetes and heart disease as well as their complications.
As an alternative to a low glycemic index diet, there is a growing body of research into products that slow the
absorption of carbohydrates through the inhibition of enzymes responsible for their digestion. These products
include alpha-amylase and glucosidase inhibitors. The common white bean (Phaseolus vulgaris) produces an alpha-
amylase inhibitor, which has been characterized and tested in numerous clinical studies. A specific and proprietary
product named Phase 2
® Carb Controller (Pharmachem Laboratories, Kearny, NJ) has demonstrated the ability to
cause weight loss with doses of 500 to 3000 mg per day, in either a single dose or in divided doses. Clinical
studies also show that Phase 2 has the ability to reduce the post-prandial spike in blood glucose levels.
Experiments conducted incorporating Phase 2 into food and beverage products have found that it can be
integrated into various products without losing activity or altering the appearance, texture or taste of the food.
There have been no serious side effects reported following consumption of Phase 2. Gastro-intestinal side effects
are rare and diminish upon extended use of the product. In summary, Phase 2 has the potential to induce weight
loss and reduce spikes in blood sugar caused by carbohydrates through its alpha-amylase inhibiting activity.
Review
Obesity is a major health hazard, with increased risk for
cardiovascular disease (mainly heart disease and stroke),
type 2 diabetes, musculoskeletal disorders (especially
osteoarthritis) and certain types of cancer (endometrial,
breast, and colon) [1]. The World Health Organization
(WHO) estimated that in 2005, approximately 1.6 billion
adults worldwide were overweight and at least 400 mil-
lion were obese. Further, the WHO estimated that at
least 20 million children under the age of 5 years were
overweight. The projected numbers for 2015 are larger,
with 2.3 billion adults expected to be overweight and
700 million expected to be obese [1].
The cause of excess body weight is an imbalance
between energy intake and expenditure. The WHO has
identified a global shift in diet towards increased intake
of energy-dense foods that are high in fat and sugars
but low in vitamins, minerals and other micronutrients.
A tt h es a m et i m et h e r ei sat r e n dt o w a r d sd e c r e a s e d
physical activity due to the increasingly sedentary nature
of many forms of work, changing modes of transporta-
tion, and increasing urbanization [1].
Control of diet and exercise are cornerstones of the
management of excess weight. A number of nutritional
approaches and diets with difference proportions of
lipids, proteins and carbohydrates have been prescribed
for weight loss. Initial guidance on weight loss was a
restriction in saturated fats. However diets low in satu-
rated fats did not necessarily result in weight loss as
expected. More recently there has been a shift towards a
reduction in carbohydrates, particularly refined carbohy-
drates, as an approach to reduce weight and the inci-
dence or related disease risk [2].
In most diets, carbohydrates are the greatest source of
calories. Carbohydrates are polyhydroxy aldehydes,
ketones, alcohols and acids that range in size from
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(polysaccharides). Before being absorbed by the body,
carbohydrates must be broken down into monosacchar-
ides. This breakdown occurs due to two major enzymes:
amylase and glucosidase [3].
Digestion of carbohydrates begins in the mouth, with
amylase secreted by salivary glands. This action accounts
for only about 5% of the breakdown of carbohydrates.
The process is halted in the stomach due to the high
acid environment destroying the amylase activity. When
the food enters the intestine, the acidic pH is neutra-
l i z e db yt h er e l e a s eo fb i c a r b o n a t eb yt h ep a n c r e a sa n d
by the mucous that lines the walls of the intestine. Amy-
lase is secreted into the small intestines by the pancreas.
Alpha-glucosidase enzymes are located in the brush bor-
der of the small intestines. Amylase breaks down the
carbohydrates into oligosaccharides. The glucosidase
enzymes (including lactase, maltase and sucrose) com-
plete the breakdown to monosaccharide units. It is only
the monosaccharide units that are absorbed into the
body. Glucose and other monosaccharides are trans-
ported via the hepatic portal vein to the liver. Monosac-
charides not immediately utilized for energy are stored
as glycogen in the liver or as fat (triglycerides) in adi-
pose tissue, liver and plasma. Carbohydrates that are
resistant to digestion in the intestine enter the colon,
where they are fermented by colonic bacteria to produce
short-chain fatty acids, carbon dioxide and methane.
Dietary carbohydrates that are composed mostly of
monosaccharide units are absorbed quickly and are said
to have a “high glycemic index”. Carbohydrates in poly-
meric form are absorbed more slowly and said to have a
“low glycemic index”. The glycemic index (GI) is defined
as the incremental area under the blood glucose curve
following ingestion of a test food, expressed as a percen-
tage of the corresponding area following an equivalent
load of a reference carbohydrate, either glucose or white
(wheat) bread [4]. Factors that influence the GI besides
the composition of the carbohydrate are the fat and pro-
tein content of the food, the acidity of the food and the
presence of fiber [5]. Low GI foods (< 55) include vege-
tables, unsweetened yogurt and protein-enriched spa-
ghetti. High GI foods (> 70) include white bread, baked
potato and dates.
After consumption of high GI foods, there is a large,
rapid increase in blood sugar levels and in response a
rapid increase in insulin levels. Insulin promotes the
uptake of glucose from the blood into cells in the liver
and skeletal muscle tissue, storing it as glycogen. Insulin
also increases fatty acid synthesis and can result in the
accumulation of lipids. Accumulation of lipids in skele-
tal muscle and the liver is associated with a decrease in
insulin sensitivity. Insulin resistance increases the
chance of developing type-2 diabetes and heart disease.
Post-prandial hyperglycemia and insulin resistance are
thought to play a central role in the development and
progression of cardiovascular disease in subjects with
impaired glucose tolerance. Post-prandial hyperglycemia
is associated with endothelial dysfunction and an
increase in intima-media thickness as well as a higher
prevalence of atherosclerotic plaques. High glucose
levels have been shown to stimulate expression of adhe-
sion molecules (intercellular adhesion molecule-1, vas-
cular adhesion molecule-1, E-selectin) and cytokines in
in-vitro models. Hyperglycemia causes an increase in
oxidative stress with associated oxidation of low-density
lipoprotein, platelet activation and thrombin generation
[5,6]. A body of evidence, including prospective cohort
studies, randomized controlled trials and mechanistic
experiments, support a role for low GI diets in the pre-
vention of obesity, diabetes and cardiovascular disease
[7-9]. Three large-scale epidemiological studies on
women reported a correlation between a high glycemic
index diet and the incidence of type 2 diabetes [10-12].
The populations studied were 59,000 US black women,
65,000 Chinese women and 91,249 US nurses, who were
each followed for periods of time of 5 to 8 years.
Another prospective cohort study in Europe, which
included 25,000 men and women, concluded that high
cereal fiber was inversely associated with the risk of
developing diabetes [13].
As previously indicated, the choice of the type of car-
bohydrate foods in the diet, with their varying glycemic
properties, with determine the rate of absorption of
sugars into the body. One means of reducing the GI of
a meal is the inclusion of resistant starches. Resistant
starches are those that resist digestion in the small
intestine, thereby passing into the large intestine, where
they act like dietary fiber [14]. These starches are natu-
rally found in seeds, legumes and unprocessed whole
grains. The amount of resistant starch in food is influ-
enced by processing, which can either increase or
decrease the amounts found in the raw substance. Resis-
tant starch can be added to foods such as bread, bis-
cuits, sweet goods, pasta, nutritional bars and cereal, in
order to lower their GI index, without affecting taste or
texture [15,16].
An alternative to a low GI diet are products that slow
the absorption of carbohydrates through the inhibition
of enzymes responsible for their digestion. These pro-
ducts include alpha-amylase and glucosidase inhibitors.
Acarbose (Prandase
®,P r e c o s e
®) is a prescription drug,
which inhibits alpha-glucosidase enzymes in the brush
border of the small intestines and pancreatic alpha-amy-
lase. Other drugs that belong to this class are miglitol
and voglibose. Acarbose reduces post-prandial hypergl-
cemia and is used to treat diabetes type-2. Clinical stu-
dies with subjects with impaired glucose tolerance have
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hyperglycemia but also cardiovascular benefits. Acarbose
has been shown to slow the progression of thickening of
the intima-media in the carotid arteries, reduce the inci-
dence of cardiovascular disease and reverse newly diag-
nosed hypertension. Recently acarbose has been
reported to improve insulin resistance in subjects with
impaired glucose tolerance or diabetes type-2. Due to
these findings, acarbose has been suggested as treatment
to reduce cardiovascular risk in subjects with metabolic
syndrome (a cluster of risk factors including high trigly-
cerides, low high-density lipoprotein cholesterol and
hypertension) [6].
Alpha-amylase inhibitors with activity against mam-
malian forms of the enzyme are present in plants and it
is suggested that they were developed by plants in order
to strengthen their defense against predators. Plant con-
stituents with enzymatic inhibitory activity include poly-
phenolic compounds and glycoproteins [17]. For
example, anthocyanins and ellagitannins present in rasp-
berries and strawberries have been reported to inhibit
alpha-glucosidase and alpha-amylase activity, respec-
tively [18]. In addition, theaflavins and catechins present
in green and black teas have been reported to inhibit
alpha-amylase and alpha-glucosidase activity as well as
retard starch digestion in an in-vitro model [19]. Alpha-
amylase inhibitors are also present in grains, including
wheat and rice [17]. However, the greatest body of
research has gone into glycoproteins extracted from kid-
ney beans (Phaseolus vulgaris) and more specifically on
the proprietary Phase 2 product.
Properties of alpha-amylase inhibitors from beans
Common beans have 3 isoforms of alpha amylase inhibi-
tor (alpha-A1, alpha-A12, alpha-AIL). The alpha-AI iso-
form has anti-amylase activity in humans. This enzyme
is found in the embryonic axes and cotyledons in the
seed and not in other organs of the plant. It is not active
against plant alpha-amylases and is therefore classified
as an anti-feedant or seed defense protein [20].
The alpha amylase inhibitor prevents starch digestion
by completely blocking access to the active site of the
alpha-amylase enzyme. Factors that affect the activity of
the alpha-AI isoform inhibitor are pH, temperature,
incubation time and the presence of particular ions. The
optimum pH for the inhibitor is 4.5 to 5.5 and the opti-
mal temperature is 22 to 37°C. There is no activity at 0°
C and the inhibitor is completely inactivated by boiling
for 10 minutes. The ideal incubation period has been
recorded as 10 minutes, 40 minutes and 120 minutes by
three different researchers [3]. The different incubation
times are thought to be due to the use of different test
conditions; namely a pH of 6.9 for the longer incubation
periods and a pH of 4.5 for the shortest [3].
Background Experiments in Humans
In the early 1980’s several products containing crude
preparations of bean amylasei n h i b i t o r sw e r em a r k e t e d
in the United States. However early clinical studies were
disappointing and it was discovered that the prepara-
tions had insufficient enzyme inhibiting activity, as well
as issues with potency and stability. Subsequently, a
research group at the Mayo Clinic developed a partially
purified white bean product and published a series of
studies exploring the activity of inhibitor in human clin-
ical studies. The test product was described as a concen-
trate: 6 to 8-fold by total protein content and 30 to 40
fold by dry weight [21]. The product was found to inac-
tivate salivary, intraduodenal and intraileal amylase
activity in vitro. Its activity was not affected by exposure
to gastric juice and only minimally by duodenal juice
(by 15%). In vitro studies demonstrated that the inhibi-
tor decreased digestion of dietary starch in a dose-
dependent manner [21]. Perfusion of the white bean
product into the duodenum of human subjects comple-
tely inhibited the activity of intraluminal amylase activity
(5.0 mg/ml at 5 ml/min) [21]. Subsequent experiments
were conducted with volunteers intubated with an oroi-
leal tube in order to obtain duodenal, jejuna and term-
inal ileal samples [22]. After intubation the subjects
ingested 50 g rice starch and on the subsequent day
they ingested starch with the amylase inhibitor (5 g or
10 g white bean extract). The white bean extract signifi-
cantly reduced duodenal, jejunal, and ileal intraluminal
amylase activity by more than 95%; it acted as quickly as
15 minutes, and for as long as 2 hours. It increased the
post prandial delivery of carbohydrates to the distal
small bowel by 22 to 24% (as measured by oroileal tube
aspiration) and increased hydrogen concentrations in
the breath from 30 to 90 minutes after the meal. Hydro-
gen breath testing is an accepted method of determining
carbohydrate malabsorption as colonic bacteria ferment
carbohydrates into organic acids, carbon dioxide and
hydrogen. A percentage of these gases are absorbed into
the portal blood stream and subsequently expired
through the lungs [23-25]. The white bean extract also
reduced the postprandial plasma glucose rose by 85%
and eliminated the subsequent fall of glucose level to
below fasting levels. The extract significantly lowered
the postprandial plasma levels of insulin, C-peptide and
gastric inhibitory polypeptide [22].
A follow-up study using subjects with diabetes melli-
tus demonstrated a decrease in the postprandial
increases in plasma glucose and insulin levels [26].
Further studies revealed that a dose of 3.8 g white bean
inhibitor could cause more than twice the amount of
hydrogen in the breath following a standard spaghetti
meal. The percentage of malabsorbed carbohydrate
increased from 4.7% to 7.0% (p < 0.05). Also, the form
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activity when taken with the spaghetti [27]. Follow-up
studies found that a dose of 2.9 g was sufficient to sig-
nificantly inhibit the postprandial increases in blood glu-
cose, C-peptide and gastric inhibitory polypeptide
following 650-calorie meal containing carbohydrate, fat
and protein [28]. A longer-term study was conducted
over 3 weeks with 6 non-insulin dependent diabetics.
The subjects were given sufficient white bean inhibitor
to reduce the increase in postprandial plasma glucose by
more than 30%: a dose of 4 to 6 g with each meal. As a
result there were significant decreases in postprandial
glucose, C-peptide, insulin and gastric inhibitory poly-
peptide along with a significant increase in hydrogen
excretion in the breath. Diarrhea and gastrointestinal
symptoms occurred the first day of administration of
the inhibitor and resolved over the next couple of days
[29]. A further experiment with 18 healthy subjects
reported that carbohydrates perfused into the ileum
delayed emptying of a meal infused into the stomach. In
one half of the subjects, the amylase inhibitor was added
to the ileum perfusate. The inhibitor significantly
reduced the absorption of carbohydrate from the ileum
and enhanced the delay in gastric emptying. Plasma
concentrations of C-peptide, glucagon, motilin, gastrin
and human pancreatic polypeptide were not influenced
by changes in gastric emptying or by the ileal perfusates.
However the delay in gastric emptying was significantly
associated with a decrease in plasma concentrations of
gastric inhibitory polypeptide and neurotensin along
with an increase in concentrations of peptide YY. This
effect was caused by the delay in gastric emptying,
rather than the other way around. Human polypeptide
levels were not changed and the authors concluded that
the hormonal changes were not mediated via the vagus
nerve [30].
Phase 2 specifications
The Phase 2
® product is a water extract of the white
kidney bean (Phaseolus vulgaris) standardized to alpha-
amylase (8;12;15;39) inhibiting units (Pharmachem
Laboratories, Kearny, NJ). Phase 2 is produced from non-
GMO whole white kidney beans, which are ground and
then extracted for 4 hours. The liquid is filtered and con-
centrated under vacuum. The extract is filtered again, and
then pasteurized before being spray dried. Phase 2 is odor-
less and tasteless. Each lot of Phase 2 has at least 3000
alpha amylase inhibiting units (AAIU) per g when tested
at a pH 6.8 using potato starch as the substrate and pan-
creatin as the enzyme source. The Phase 2 extraction pro-
cess was designed to make it more potent and stable than
the white bean product tested by the Mayo clinic.
Phase 2 is used as a dietary supplement in various
forms, including powders, tablets, capsules and
chewables. There are approximately 200 brands of nutri-
tional supplement/weight loss products in the worldwide
market that contain Phase 2. A typical dose is 1 to 2
capsules, each containing 500 mg, taken before each of
3 daily meals, for a total of 1500 to 3000 mg per day. A
private safety panel approved a maximum daily intake of
10,000 mg (10 g) [31].
Experiments conducted incorporating Phase 2 into
food products have found that it can be incorporated
into chewing gum, mashed potatoes, yeast-raised dough
(bread, pizza, etc) without losing activity or altering the
appearance, texture or taste of the food [32-34].
Clinical studies conducted with Phase 2
Ten clinical studies have demonstrated weight loss over
time following administration of Phase 2. Three studies
demonstrated significant loss of body weight with Phase
2 compared to a placebo control in people who are
overweight or obese. The doses ranged from 445 mg for
4 weeks to 3000 mg for 8 to 12 weeks [35-37]. A pla-
cebo controlled study by showed a comparative loss in
body weight only when subjects were stratified by diet-
ary carbohydrate intake. Those who consumed the
greatest amount of carbohydrate, lost significant body
weight in comparison to the placebo group [38]. Six
additional studies reported a loss of weight over time
[39-44]. Three clinical studies reported a reduction in
serum triglycerides over time [40,41,44] (Table 1).
Weight loss - compared to placebo
A 12 week randomized double-blind placebo controlled
trial included 60 overweight individuals (BMI between
24 and 32 kg/m
2). The subjects consumed 2 soft chews
before each meal containing either Phase 2 (500 each
mg) or placebo for 12 weeks. The Phase 2 group con-
sumed a total of 3000 mg Phase 2 per day. A total of 88
m e na n dw o m e ne n r o l l e di nt h es t u d y ,w h i l e6 0c o m -
pleted the study and were included in the analyses.
There was a statistically significant weight reduction in
t h ea c t i v eg r o u pc o m p a r e dw i t ht h ep l a c e b og r o u pa t
weeks 6, 8 and 12. The amount of weight lost by the
a c t i v eg r o u pa t1 2w e e k sw a s6 . 9± 7 . 9l b s( a v e r a g eo f
0 . 5 7 5l b sp e rw e e k )w h i l et h ep l a c e b og r o u pg a i n e d0 . 8
lbs ±6.1 (p = 0.029 between groups). There were no sig-
nificant differences between groups in body fat, lean
body mass or body measurements (waist/hip circumfer-
ences). No adverse events were reported [36].
A randomized, double-blind, placebo-controlled
study was conducted with 60 slightly overweight sub-
j e c t s( 5t o1 5k go v e r w e i g h t ) .T h es u b j e c t sw e r e
r e q u i r e dt oh a v eas t a b l ew e i g h tf o rt h ep a s t6m o n t h s
and underwent a 2-week single-blinded, run-in period
prior to randomization. The subjects took 1 tablet
(active or placebo) per day for 30 consecutive days
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orie diet). The active tablet contained 445 mg Phase 2
and 0.5 mg chromium picolinate (≈55 mcg elemental
chromium). After 30 days, the active group had a sig-
nificant reduction in body weight, BMI, fat mass, adi-
pose tissue thickness and waist/hip/thigh
circumferences while maintaining lean body mass. The
active group lost an average of 2.93 kg (6.45 lbs) in 30
days compared with an average of 0.35 kg (0.77 lbs) in
the placebo group (p < 0.001). BMI in the test group
was reduced from an initial 25.9 ± 2.0 (SEM) to 24.9 ±
1.9 (p < 0.01). The placebo showed no significant
change from the initial 26.0 ± 2.3 (SEM). Body compo-
sition was measured with bioelectrical impedance. The
active group demonstrated a 10.45% reduction in body
fat compared with a 0.16% reduction in the placebo
group (p < 0.001). Waist and hip circumferences mea-
sured in a standard way, showed the same pattern as
well. The active group demonstrated 2.93 cm and 1.48
cm reductions respectively, compared with 0.46 cm
and 0.11 cm reductions in the placebo group (p <
0.001). No adverse events were reported [35].
A randomized, double-blind, placebo-controlled study
was conducted in China with 101 volunteers who had a
BMI between 25 and 40. The subjects were given a
single capsule containing 1000 mg Phase 2 or placebo
three times per day, just before meals, for 60 days. The
active group ingested a total of 3,000 mg Phase 2 per
day. As a result, there was significant weight loss in the
active groups compared to the placebo group after 30
and 60 days. After 60 days, the average weight loss in
the active group was 1.9 ± 0.15 kg compared to 0.4 ±
0.13 kg in the placebo group (p < 0.001). There was also
a significant reduction in waist measurement in the
active group compared to the placebo group (1.9 ± 0.32
cm compared to 0.4 ± 0.26 (p < 0.001). There was no
effect on hip measurements. Blood chemistries did not
change significantly over the 2 month study and no
adverse side effects were reported [37].
A 4-week, randomized, double-blind, placebo-con-
trolled study conducted with 25 healthy overweight
(BMI 25-30) subjects [38]. The subjects took 1000 mg
of Phase 2
® or an identical placebo twice a day (before
breakfast and lunch) as part of a weight loss program
which included diet, exercise and behavioral interven-
tion. The subjects were given nutritional guidelines to
standardize their caloric intake at 1800 Kcal/day. Break-
fast and lunch were provided to increase compliance. In
addition, subjects met with a personal trainer to estab-
lish an exercise program and had a counseling session
Table 1 Phase 2 Clinical Data
Reference
(Author, date)
Study Design/
Duration
Subjects Purpose Preparation/Dose Main Results
Thom, 2000 [39] RPCT, 12 weeks n = 40 (BMI 28-39) weight loss 400 mg Phaseolamin
® 3X
after meals, total 1200 mg/
day (other ingred. inulin
&Garcinia extract)
↓body weight, BMI & %body fat in
active group (p < 0.05), no effect in
placebo group; no between group
analysis
Erner, 2003 [40] RPCT, 12 weeks,
then open 12
weeks
n = 54 (BMI 24-36) weight loss Thera-Slim: 1000 mg Phase2
before 2 meals, total 2000
mg/day
trend toward ↓body weight, 3X
decrease in triglycerides; no
between group analysis
Rothacker, 2003 [36] RPCT, 12 weeks n = 88 (BMI 24-32) weight loss StarchAway chews: 1000 mg
Phase2 before 3 meals, total
3000 mg/day
↓body weight comparison to
placebo (p < 0.05)
Udani, 2004 [44] RPCT, 8 weeks n = 39 (BMI 30-43) weight loss Phase 2 1500 mg 2X, 3000
mg/day
↓body weight comparison to
placebo (ns) ↓trigylcerides (ns)
Koike, 2005 [41] Open, 8 weeks n = 10 (BMI 23-30) weight loss 3 capsules Phaseolamin 1600
diet 2X daily; 750 mg Phase 2
daily
↓body weight (p = 0.002), calorie
intake, BMI, triglycerides & HDL (all
p < 0.05)
Osorio, 2005 [42] Open, 30 days n = 39 (overweight
& obese)
Weight loss PreCarb capsules: 1000 mg
Phase3 with meals, total 3000
mg/day
↓body weight & ↓waist to hip ratio
over time (both p < 0.001)
Celleno, 2007 [35] RPCT, 30 days n = 60 (BMI avg 26) Weight loss Phase 2 + chromium; 445 mg
extract daily
↓body weight (p < 0.001), BMI,
body fat (both p < 0.01)
Vinson, 2009 [45] PCT, X-over, single
dose
Part 1: n = 11, Part
2: n = 7
Plasma
glucose
Phase 2 mixed with
margarine or gravy. 750 or
1500 mg.
↓AUC post prandial blood glucose;
higher dose (p < 0.05).
Udani, 2009 [46] RPC, X-over, single
dose
n = 13 (BMI 18-25) Plasma
glucose
Phase 2 capsules or mixed w/
butter. 1500, 2000, 3000 mg
↓AUC post prandial blood glucose;
3000 mg w/butter (p < 0.05).
Wu, 2010 [37] RPCT, 60 days n = 101 (BMI 25-40) Weight loss Phase 2; 1,000 mg 3X daily ↓body weight, waist circumference
(both p < 0.01)
DB = double-blind, PCT = placebo-controlled trial, RPCT = randomized placebo-controlled trial, X-over = crossover.
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barriers to weight loss. As a result of this intervention,
both groups reduced weight and waist size significantly
compared to baseline, but there were no significant dif-
ferences between groups. After 4 weeks, the active
group lost 6.0 lbs and the placebo group lost 4.7 lbs
compared to baseline (p = 0.0002 active and p = 0.0016
placebo). The active group lost a mean of 2.2 in inches
from their waists and the control group lost 2.1 inches
from their waists compared to baseline (p = 0.050 and
0.0001, respectively). For exploratory analysis, subjects
were stratified by dietary carbohydrate intake. In this
analysis, the tertile that took in the most carbohydrates
demonstrated significantly greater loss of body weight
compared with the placebo group (8.7 pounds vs. 1.7
pounds, p = 0.04). This group also had a significantly
greater loss in inches around the waist (3.3 vs 1.3
inches; p = 0.01). There were no significant changes
from baseline in hip circumference, triglycerides, fasting
glucose, total cholesterol, appetite control, hunger,
energy level, and percent body fat, neither were there
any significantly differences between groups. No side
effects or adverse events were reported [38].
Weight loss - over time
In a randomized double blind placebo controlled trial,
forty healthy overweight (BMI 27.5 to 39.0) were rando-
mized and instructed to take 2 tablets of the test pro-
duct immediately after all 3 meals (breakfast, lunch and
dinner) for 12 weeks [39]. Subjects were also instructed
to follow a 1200 kcal/day low-fat diet. The tablets, 650
mg each, contained a proprietary blend (Suco-Bloc
®)
including 200 mg of Phase 2 (Phaseolamin
®,L e u v e n
Bioproducts, Belgium), 200 mg of inulin (from chicory
root), and 50 mg of Garcinia cambogia extract. The
remaining 200 mg in the tablets were not described. All
subjects were included in an intent-to-treat analysis,
including 7 subjects who dropped out of the study (6 in
the placebo arm, 1 in the active arm). After 12 weeks,
the active group had a significant reduction in weight,
BMI and percent body fat compared to baseline,
whereas there was no significant change in the placebo
group. The active group lost an average of 3.5 kg (7.7
lb; p = 0.001) and the placebo group lost 1.3 kg (2.9 lb).
BMI decreased by 1.3 kg/m
2 (p = 0.01) in the active
group and by 0.5 kg/m
2 in the placebo group. Percent
body fat (measured by bioelectrical impedance)
decreased by 2.3% (p = 0.01) in the active group and by
0.7% in the placebo. Body mass analyses showed that
the weight loss in the active group consisted mainly of
fat loss as >85% of the weight loss was accounted for by
fat. Between group analyses was not provided for any of
the variables. No adverse events were reported in either
group [39].
A 12 week double-blind, placebo-controlled study was
conducted and this period was followed by an additional
12 weeks were in all the participants received the active
treatment [40]. In the first part of the study, the subjects
took 2 capsules twice a day of placebo or Thera-Slim™.
Thera-Slim™ capsules contained 500 mg Phase 2 plus
250 mg fennel seed powder. The placebo contained cel-
lulose and fennel seed powder. The active group
received a total of 2000 mg Phase 2 per day. The sub-
jects were asked to eat a diet in which lunch and dinner
contained 100 to 200 g of carbohydrates. Sixty over-
weight and obese adult subjects (BMI 24-36) were ran-
domized and 54 completed the study. After the first 12
weeks, the active group lost a average of 1.4 lbs and the
placebo gained an average of 0.6 lbs. Serum triglyceride
levels dropped by almost 3.3 times in the active group
compared to the placebo group (-38.1 vs -11.9). The
levels of total cholesterol and HDL were similar in both
groups. No between group analyses were included in the
report. There were no adverse events reported after 24
weeks of usage.
A randomized double blind placebo controlled study
was conducted with 39 obese subjects (BMI 30-43) who
were randomly allocated to receive either 1500 mg of
Phase 2 or an identical placebo twice daily with lunch
and dinner for 8 weeks [44]. The active group received
a total of 3000 mg Phase 2 per day. Subjects were
instructed to consume a controlled high fiber/low fat
diet that provided 100 to 200 g of complex carbohydrate
intake per day. Subjects were also instructed to eat the
majority of their carbohydrates during lunch and dinner
since those were the meals at which the Phase 2 or pla-
cebo were taken. The amount of carbohydrate intake
was determined for the subjects on the basis of their
estimated daily maintenance carbohydrate requirement.
Twenty seven subjects completed the study (14 active
and 13 placebo). After 8 weeks the active group lost an
average of 3.79 lbs. (an average of 0.47 lbs. per week)
compared with the placebo group which lost an average
of 1.65 lbs. (an average of 0.21 lbs. per week). The dif-
ference was not statistically significant with a two tailed
p-value of 0.35. Triglyceride levels in the Phase 2 group
were reduced by an average of 26.3 mg/dl. This reduc-
tion was more than three times the average reduction of
8.2 mg/dl seen in the placebo group (p = 0.07).
Several secondary outcomes were measured during the
study including body fat percentage, waist and hip cir-
cumferences, energy level, hunger, appetite, HbA1c, and
total cholesterol. For each of these secondary measures,
no clinically or statistically significant differences were
identified between the active and the placebo group. No
adverse events occurred that were felt to be due to the
active product. One placebo subject experienced abdom-
inal pain, bloating and gas while one active group
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headaches. There were no clinically significant changes
in biochemical indicators of safety, including serum
electrolytes, and markers of kidney and liver function
[44].
Weight loss - open studies
An open study was conducted with 10 healthy subjects
(5 men and 5 women) with a BMI between 23 and 30
and a body fat ratio of over 25% for men and over 30%
for women [41]. The subjects took 3 capsules of Phaseo-
lamin™ 1600 diet twice a day, 30 min before lunch and
dinner, for 8 weeks. The six capsules (1.5 g) contained
750 mg Phase 2, 200 mg clove, 20 mg lysine, 20 mg
arginine, 20 mg alanine.
Over the course of 8 weeks, caloric intake decreased
from 1742 ± 254 kcal/day to 1525 ± 249 kcal/day (p =
0.01) and the subjects lost a significant amount of
weight (2.4%; 74.5 ± 7.3 to 72.7 ± 7.8; p = 0.002). There
were also a significant reduction in body fat (p < 0.001)
and BMI (p = 0.002). There were reductions in waist
and of hip circumferences, without a significant change
in the ratio of waist to hip circumference. Over the 8
weeks there were significant reductions in systolic and
diastolic blood pressure (p = 0.01 and p < 0.001). There
were also significant reductions in triglycerides (p =
0.019) and HDL cholesterol (p = 0.001), but not in total
cholesterol or LDL cholesterol. There was no change in
blood glucose levels and no adverse events were
reported [41].
An open study was conducted with 50 healthy adult
subjects who were overweight or obese. They were
given Precarb (Natrol’s Carb Intercept 500 mg capsules)
containing Phaseolamin/Phase2 [42]. The subject took 1
g Precarb (2 capsules, 3 times daily with high carbohy-
drate meals) for 30 days. A per-protocol analysis was
conducted on the 37 to 39 subjects who completed the
study. There was a significant reduction in mean body
weight of 2.34 ± 2.21 kg (n = 37; p < 0.001) and a signif-
icant reduction in mean waist-to-hip ratio 2.77 ± 2.55 (n
= 39; p < 0.001).
In an open label study 23 adult men and women (BMI
22) took “Super Bows Diet Type B”, a granular food
available in Japan that contains 500 mg Phase 2, Coleus
forskohlii extract and mushroom chitosan (Plus fort
Barrious
®) for a period of 8 weeks [43]. Bows Diet Type
B was taken as 1 packet of powder in a glass of water
20 minutes before lunch and dinner. After 8 weeks, the
product caused a significant decrease in body weight
(0.78 ± 0.20 kg, p < 0.01) and percent body fat (1.19 ±
0.37%, p < 0.01). There was no change on calorie intake
during this period. In 10 subjects who had a BMI over
24 and a total cholesterol over 220 mg/dl, there was a
significant decrease in cholesterol after 4 and 8 weeks
(25.3 ± 7.1 mg/dl and 11.3 ± 4.0 mg/dl, respectively;
both p < 0.05). There were temporary gastrointestinal
symptoms such as bloating and constipation but these
symptoms disappeared following a few days of continu-
ous intake of the product.
Glycemic Index (GI)
Four cross-over clinical studies addressed the potential
effect of Phase 2 on post-prandial increases in blood
sugar. All four studies indicated that Phase 2 could
reduce post-prandial spikes in blood sugar with a sug-
gestion that the effect is dose-related.
In the first study, a placebo-controlled, cross-over
study, eleven fasting subjects (men and women aged 21
to 57) were given 4 slices of white bread and 42 g (3
Tbs) of margarine with or without 1500 mg of Phase 2
(the Phase 2 was added to the margarine) [45]. The
food contained a total of 610 calories, 60.5 of which
came from carbohydrate. The tests were administered a
week apart. Absorption and metabolism of carbohydrate
was measured as levels of plasma glucose over time. In
comparison to control, the glucose levels following con-
sumption of Phase 2 returned to baseline 20 minutes
e a r l i e r .T h ea r e au n d e rt h e plasma glucose vs. time
curve was 66% lower with Phase 2 compared to the con-
trol (p < 0.05). The authors concluded that this indi-
cated that 1/3
rd of the carbohydrate in the bread was
absorbed. However, actual absorption and subsequent
excretion was not measured.
The second study, published in the same paper, was
also a placebo-controlled, cross-over study. Seven sub-
jects (men and women 23 to 43 years old) were given
a frozen dinner containing country fried steak, mash
potatoes, green beans and cherry-apple pie (630 cal-
ories with 64 g carbohydrate) with and without 750
mg Phase 2. In this study, the Phase 2 was mixed with
t h eg r a v y .T h ee f f e c to fP h a s e2w a st or e d u c et h e
average plasma glucose vs. time curve by 28% and the
authors concluded that 2/3rds of the carbohydrate in
the meal was absorbed. The authors noted that there
appeared to be a dose-related effect with the 1500 mg
dose of Phase 2 being twice as effective as the 750 mg
dose [45].
A 6-arm crossover study was conducted with 13 ran-
domized subjects (BMI 18-25) to determine whether the
addition of Phase 2 would lower the GI of a commer-
cially available high glycemic food (white bread) [46].
Standardized GI testing was performed using capillary
blood glucose measurements following ingestions of
white bread with butter, with and without the addition
of Phase 2 in capsule or powder form. In both formula-
tions, Phase 2 was given in dosages of 1500 mg, 2000
mg, and 3000 mg. The powdered form was mixed with
the butter. Statistical analysis was performed by one-way
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multiple comparisons (t tests) to the white bread con-
trol. For the capsule formulation, the 1500 mg dose had
no effect on the GI and the 2000 mg and 3000 mg cap-
sule doses caused insignificant reductions in GI. For the
powder, the 1500 mg and 2000 mg doses caused insig-
nificant reductions in the GI, while the 3000 mg dose
caused a significant reduction in post-prandial glucose
levels (a reduction of 34.11%, p = 0.023).
A single dose double-blind cross-over test was con-
ducted on the effects of Super Bows Diet Type B on
blood sugar levels [43]. As previously stated, this pro-
duct is a granular food available in Japan that contains
500 mg Phase 2, Coleus forskohlii extract and mush-
room chitosan. The experiment included 13 men and
women with a fasting blood glucose level above 126 mg/
dl. In two test periods 1 week apart, the subjects took a
packet of product or placebo along with a glass of water
5 minutes before eating 300 g polished rice. Blood sam-
ples were taken before the intake of the rice and 30, 60,
90 and 120 minutes afterward. Blood sugar levels 30
minutes after eating the rice were significantly lower
with the test product (p < 0.01). Plasma insulin levels
were significantly lower compared to the control at 30
and 60 minutes after consuming the rice (p < 0.01).
Safety
In the human clinical studies reviewed above there were
no reports of serious side effects resulting from inges-
tion of white bean extracts. Clinical efficacy studies
using doses of Phase 2 up to 3000 mg per day in divided
doses for periods of 30 days to 24 weeks also reported
no significant adverse events. An acute animal toxicity
study was conducted in rats with Phase 2 at doses of
500 to 5000 mg/kg body weight along with a subchronic
study of 90 days with doses of 200 to 1000 mg/kg. In
response, there were no adverse reactions and signs of
toxicity in biochemical and histopathological analysis
[47]. A 28-day toxicity study conducted with male and
female rats reported a no-adverse-effect level (NOAEL)
of 2500 mg/kg/day [48]. Cantox Health Sciences Inter-
national conducted a safety review of published and
unpublished data on Phase 2 and the panel of experts
concluded that it could be safety consumed at doses up
to 10 g per day [31].
Since alpha-amylase inhibitors prevent the degradation
of complex carbohydrates into oligosaccharies, those
carbohydrates will pass through the intestine into the
colon. In the colon, bacteria will digest the complex car-
bohydrates, and this may initially cause gastrointestinal
side-effects such as flatulence and diarrhea. In the study
conducted with Super Bows Diet Type B which con-
tained Phase 2 along with other ingredients, there were
temporary gastrointestinal symptoms including bloating
and constipation but these symptoms resolved with con-
tinued intake of the product [43].
Raw beans contain phytohaemagglutinin (PHA) at high
levels which have been associated with toxic effects in ani-
mals and severe gastrointestinal disturbances in humans
[3]. However, PHA levels in beans are drastically reduced
by cooking. In addition, white beans have negligible
amounts of PHA compared to colored beans. Phase 2 is a
standardized white bean extract prepared using a specia-
lized process which substantially inactivates haemaggluti-
nating activity (HA) and trypsin inhibiting activity (TIA).
The finished product contains less than 700 HA units per
g and less than 20 TIA units per mg dry weight [31].
Product equivalency
This review is focused on the development and clinical
research of a proprietary product, Phase 2 Carb Control-
ler (Pharmachem Laboratories, Kearny, NJ). We felt it
was important to focus on this product as there is no
evidence that carbohydrate blockers are equivalent.
Early studies on the alpha-amylase inhibitor from white
bean indicated that enzyme stabilization through specific
manufacturing processes was key to an active product.
The challenge of establishing biological equivalency for
protein biopharmaceuticals has been highlighted in
recent publications. The complexity of these molecules,
and their production in living cells, makes the final pro-
duct sensitive to changes in manufacturing conditions.
Because of this, the European Medicine Agency has
introduced a new regulatory pathway for biosimilars
(also known as follow-on biologics) which mandates
clinical trials in order to show therapeutic equivalence
[49]. In the US, companies are expected to use the
approval process for new branded drugs [50]. While the
Phase 2 product is a dietary supplement, and not a
pharmaceutical, we believe similar principals apply.
Conclusions
Experiments conducted with the Phase 2 alpha-amylase
inhibitor indicate that it reduces the rate of absorption of
carbohydrates, thereby reducing the GI of foods. The evi-
dence also indicates that Phase 2 promotes weight loss
when taken concurrently with meals containing carbohy-
drates. The importance of reducing the GI of foods in
weight management and type 2 diabetic control is indi-
cated by an emerging body of evidence. Reducing the
post-prandial spikes of glucose and insulin following a
high GI meal may also reduce the risks of developing
insulin resistance, which can lead to cardiovascular
disease.
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